<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Benzodiazepine poisoning</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Benzodiazepine poisoning</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Benzodiazepine poisoning</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Howard Greller, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amit Gupta, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert G Hendrickson, MD, FACMT, FAACT</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ganetsky, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 11, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Benzodiazepines (BZDs) are sedative-hypnotic agents that have been in clinical use since the 1960s. BZDs are safer than older sedative-hypnotic agents, such as barbiturates, and thus are commonly used for sedation and to treat anxiety, seizures, withdrawal states, insomnia, and agitation. They are also frequently combined with other medications for procedural sedation. Due to their many uses and wide therapeutic index, BZDs are widely prescribed, and nearly 50 different agents are available worldwide. The high incidence of BZD overdose mirrors their widespread use and availability [<a href="#rid1">1-4</a>]. </p><p>BZDs are also commonly misused and diverted. The pediatric rate of misuse, severity of outcomes, and presence of co-ingestants have steadily increased since 2000, especially in adolescents [<a href="#rid5">5</a>]. <a class="drug drug_general" data-topicid="8453" href="/z/d/drug information/8453.html" rel="external">Alprazolam</a>, <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">clonazepam</a>, and <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> are the most commonly misused BZDs by both adolescents and adults, but misuse of designer benzodiazepines not approved for any medical indication by the United States Food and Drug Administration (eg, etizolam, bromazolam) is being increasingly recognized.</p><p>The diagnosis and management of acute BZD poisoning will be reviewed here. A general approach to the poisoned patient and the evaluation of stupor and coma are discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/324.html" rel="external">"General approach to drug poisoning in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13850.html" rel="external">"Initial management of the critically ill adult with an unknown overdose"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6496.html" rel="external">"Approach to the child with occult toxic exposure"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5104.html" rel="external">"Stupor and coma in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6225.html" rel="external">"Evaluation of stupor and coma in children"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">PHARMACOLOGY</span><span class="headingEndMark"> — </span>BZDs exert their effect via modulation of the gamma-aminobutyric acid A (GABA-A) receptor. Gamma-aminobutyric acid (GABA) is the chief inhibitory neurotransmitter of the central nervous system.</p><p>The GABA-A receptor is a ligand-gated ion channel composed of five subunits arranged in various combinations of alpha, beta, and gamma [<a href="#rid6">6-11</a>]. The composition of subunits determines the affinity of the various xenobiotics that bind to the receptor. BZDs bind at the interface of the alpha and gamma subunits and, once bound, lock the GABA-A receptor into a conformation that increases its affinity for GABA (which binds between alpha and beta subunits). BZDs do not alter the synthesis, release, or metabolism of GABA but rather potentiate its inhibitory actions by augmenting receptor binding. This binding increases the frequency of the flow of chloride ions through the GABA ion channel, causing postsynaptic hyperpolarization and a decreased ability to initiate an action potential. </p><p>The low incidence of respiratory depression with orally ingested BZDs appears to be related to the low density of binding sites in the brainstem respiratory center [<a href="#rid10">10</a>]. However, BZDs combined with opioids (or other sedative-hypnotic agents) act synergistically to depress medullary respiratory drive and increase the risk of hypoventilation and apnea.</p><p class="headingAnchor" id="H3"><span class="h1">PHARMACOKINETICS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Absorption/distribution</strong> - BZDs are rapidly absorbed in the gastrointestinal tract, and most are highly lipophilic and highly protein bound.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism/elimination</strong> - BZDs are primarily hepatically metabolized, most by the CYP2C19 and CYP3A4 enzymes. <a class="drug drug_general" data-topicid="8453" href="/z/d/drug information/8453.html" rel="external">Alprazolam</a> and <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">midazolam</a> are metabolized by CYP3A4. <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">Diazepam</a> is metabolized by both CYP3A4 and CYP2C19. <a class="drug drug_general" data-topicid="9726" href="/z/d/drug information/9726.html" rel="external">Oxazepam</a>, <a class="drug drug_general" data-topicid="9973" href="/z/d/drug information/9973.html" rel="external">temazepam</a>, and <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> are directly conjugated to an inactive, water-soluble glucuronide metabolite that is excreted by the kidney [<a href="#rid12">12,13</a>]. <a class="drug drug_general" data-topicid="9243" href="/z/d/drug information/9243.html" rel="external">Chlordiazepoxide</a>, diazepam, and <a class="drug drug_general" data-topicid="8469" href="/z/d/drug information/8469.html" rel="external">flurazepam</a> are metabolized to active metabolites, which are then conjugated and excreted [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1">BZDs are commonly divided into three groups based upon elimination half-life duration: short-acting (half-life of less than 12 hours), intermediate-acting (half-life between 12 and 24 hours), and long-acting (half-life greater than 24 hours) BZDs  (<a class="graphic graphic_table graphicRef69184" href="/z/d/graphic/69184.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1">Short-acting BZDs, such as <a class="drug drug_general" data-topicid="10017" href="/z/d/drug information/10017.html" rel="external">triazolam</a>, <a class="drug drug_general" data-topicid="8453" href="/z/d/drug information/8453.html" rel="external">alprazolam</a>, and <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">midazolam</a>, generally have few active metabolites, do not accumulate with repeated doses, and demonstrate clearance that is largely unaffected by age and liver disease. Midazolam has a short half-life, very rapid onset of clinical effect, and a shorter duration of action than other BZDs, which explains its preferential use in procedural sedation [<a href="#rid14">14</a>]. However, successive doses of midazolam lead to bioaccumulation of its hydroxy-metabolites and may prolong the drug's sedative effects [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/z/d/html/264.html" rel="external">"Procedural sedation in adults in the emergency department: General considerations, preparation, monitoring, and mitigating complications"</a>.)</p><p></p><p class="bulletIndent1">Long-acting BZDs, such as <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a> and <a class="drug drug_general" data-topicid="9243" href="/z/d/drug information/9243.html" rel="external">chlordiazepoxide</a>, generally have pharmacologically active metabolites, accumulate in tissues after multiple doses, and demonstrate impaired clearance in older patients and those with liver disease. [<a href="#rid16">16-18</a>]. The main active metabolite of diazepam is desmethyldiazepam. Diazepam's other active metabolites include <a class="drug drug_general" data-topicid="9973" href="/z/d/drug information/9973.html" rel="external">temazepam</a> and <a class="drug drug_general" data-topicid="9726" href="/z/d/drug information/9726.html" rel="external">oxazepam</a>. Active metabolites of chlordiazepoxide include desmethylchlordiazepoxide, demoxepam, desmethyldiazepam, and oxazepam.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug interactions</strong> – Drugs that are metabolized by CYP450 enzymes can interact with BZDs, potentially prolonging or decreasing their clinical effects [<a href="#rid16">16-18</a>]. Examples of common drugs that inhibit the CYP3A4 enzyme and reduce the metabolism of BZDs, thereby prolonging their effects, are shown in the table  (<a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">table 2</a>). Since <a class="drug drug_general" data-topicid="9726" href="/z/d/drug information/9726.html" rel="external">oxazepam</a>, <a class="drug drug_general" data-topicid="9973" href="/z/d/drug information/9973.html" rel="external">temazepam</a>, and <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> do not undergo hepatic metabolism, they are less likely to be affected by CYP450 interactions [<a href="#rid14">14,15</a>].</p><p></p><p class="headingAnchor" id="H4198177814"><span class="h1">DESIGNER BENZODIAZEPINES</span><span class="headingEndMark"> — </span>Novel commonly misused designer benzodiazepines (BZDs) include etizolam, clonazolam, bromazolam, flubromazolam, <a class="drug drug_general" data-topicid="8697" href="/z/d/drug information/8697.html" rel="external">bromazepam</a>, flubromazepam, and flualprazolam [<a href="#rid19">19-21</a>]. These agents have been found in counterfeit <a class="drug drug_general" data-topicid="8453" href="/z/d/drug information/8453.html" rel="external">alprazolam</a> tablets or combined with illicit opioids [<a href="#rid22">22</a>]. </p><p>Bromazolam and flubromazolam are structurally similar to <a class="drug drug_general" data-topicid="8453" href="/z/d/drug information/8453.html" rel="external">alprazolam</a> and may have similar risk for development of dependence and withdrawal [<a href="#rid22">22,23</a>]. (See  <a class="medical medical_review" href="/z/d/html/141183.html" rel="external">"Benzodiazepine withdrawal"</a>.)</p><p>In a small case series, bromazolam was associated with hyperthermia, seizures, and myocardial injury, but other factors (eg, sedative withdrawal, potential co-ingestants) may have contributed to the clinical effects [<a href="#rid24">24</a>].</p><p>Etizolam (also called "tizzies" or "street vallies"), a commonly misused thienotriazolodiazepine (BZD-like sedative) that binds to the BZD receptor, is available by prescription in Japan and India and has been associated with fatalities [<a href="#rid25">25,26</a>].</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL FEATURES OF OVERDOSE</span></p><p class="headingAnchor" id="H5"><span class="h2">Sedation</span><span class="headingEndMark"> — </span>The classic presentation of a patient with an isolated BZD overdose consists of central nervous system depression with unremarkable vital signs ("coma with normal vitals"). Many patients are arousable and able to provide an adequate history. Other signs include slurred speech, nystagmus, and ataxia.</p><p class="headingAnchor" id="H660744300"><span class="h2">Ataxia</span><span class="headingEndMark"> — </span>In young children (five years old and younger), ataxia has been described as the most common sign of BZD toxicity, even more prevalent than central nervous system depression. Children can also present with isolated ataxia without somnolence [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H2952960772"><span class="h2">Respiratory depression</span><span class="headingEndMark"> — </span>Respiratory compromise is uncommon with isolated oral ingestions but may occur with a sedative co-ingestion or following rapid intravenous (IV) administration. Sedative co-ingestants, such as an opioid or ethanol, increase the risk for dangerous complications such as synergistic respiratory depression [<a href="#rid28">28-30</a>]. Many intentional BZD ingestions involve a co-ingestant, commonly ethanol [<a href="#rid31">31</a>]. Even though BZDs have a wide margin of safety, respiratory depression is more likely to occur after IV administration (eg, during procedural sedation) due to a rapid rise in central nervous system concentrations leading to greater clinical effects [<a href="#rid32">32</a>].</p><p>There is significant interindividual variability in BZD-induced respiratory compromise that depends upon many factors, including tolerance, weight, age, co-ingestants, and genetics. </p><p class="headingAnchor" id="H6"><span class="h2">Parenteral diluent toxicity</span><span class="headingEndMark"> — </span>Propylene glycol toxicity can occur in patients receiving prolonged parenteral administration of <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a> or <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a>, which contain propylene glycol (1,2 propanediol) as a diluent. The classic toxicity is an elevated anion gap metabolic acidosis with elevated lactate; other potential effects are skin and soft tissue necrosis (from extravasation), hemolysis, cardiac dysrhythmias, hypotension, seizure, coma, and multisystem organ failure. </p><p>An elevated osmolal gap correlates with elevated propylene glycol concentrations and can be used as a surrogate marker of toxicity [<a href="#rid33">33</a>]. Propylene glycol poisoning from IV BZD infusions is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/1616.html" rel="external">"Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects", section on 'Propylene glycol toxicity'</a>.)</p><p class="headingAnchor" id="H2483881009"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H3074682126"><span class="h2">Confirmed by history</span><span class="headingEndMark"> — </span>BZD poisoning is a clinical diagnosis and usually suspected on the basis of clear corroborating history in a sedated patient. The diagnosis can be made in the following circumstances that support the history, although this is not an exhaustive list:</p><p class="bulletIndent1"><span class="glyph">●</span>Patient admits to a BZD ingestion</p><p class="bulletIndent1"><span class="glyph">●</span>The BZD ingestion was witnessed</p><p class="bulletIndent1"><span class="glyph">●</span>A recently filled empty bottle of BZD pills is found near the patient</p><p class="bulletIndent1"><span class="glyph">●</span>The patient left a suicide note</p><p class="bulletIndent1"><span class="glyph">●</span>Parents noticed pill fragments in a young child's mouth</p><p></p><p class="headingAnchor" id="H3650460296"><span class="h2">Suspected but not confirmed</span><span class="headingEndMark"> — </span>In the absence of clear corroborating history, BZD poisoning should be considered a diagnosis of exclusion. Non-toxicologic and other toxicologic etiologies must be ruled out, especially conditions in which diagnostic delay will hold up critical interventions and definitive care. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>A positive urine BZD test result is <strong>not</strong> diagnostic because it only confirms BZD use at some point in the recent past and not poisoning or etiology of the altered mental status. A negative urine BZD result does <strong>not</strong> exclude the diagnosis as these tests are not sensitive for all BZDs. Limitations of urine BZD screens are discussed further below. (See <a class="local">'Urine testing'</a> below.)</p><p>We do not routinely administer the antidote <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">flumazenil</a> to establish the diagnosis when BZD poisoning is strongly considered to be the etiology of the patient's mental status and instead prefer to rule out other etiologies and observe the patient for clinical improvement. However, in young children (ie, five years old and younger) with altered mental status suspected from a BZD ingestion, we would administer flumazenil to aid in confirming the diagnosis. (See <a class="local">'Commonly accepted indications'</a> below.) If the child's mental status or neurologic impairment, such as ataxia, resolves after flumazenil administration, this confirms the diagnosis and avoids an extensive and potentially invasive evaluation.</p><p>Other experts have broader indications in adults for use of <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">flumazenil</a> to aid in confirming BZD ingestion as the etiology of a patient's altered mental status (see <a class="local">'Controversial indications'</a> below). If the patient's lethargy improves after flumazenil administration, this confirms that a BZD contributed to the altered mental status but does not necessarily exclude co-ingestions, other neurologic issues, or comorbid conditions. It may provide an opportunity to obtain further history from the patient and confirm if a BZD ingestion contributed to the altered mental status.</p><p class="headingAnchor" id="H1996527424"><span class="h1">GENERAL DIAGNOSTIC TESTING</span></p><p class="headingAnchor" id="H3891822816"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Routine laboratory and diagnostic testing of the patient with sedation, including when a BZD ingestion is suspected, is aimed at excluding other diagnoses and includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Fingerstick blood glucose to rule out hypoglycemia as the cause of altered mental status</p><p class="bulletIndent1"><span class="glyph">●</span>Serum <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>, salicylate, and ethanol concentrations to rule out these common co-ingestions</p><p class="bulletIndent1"><span class="glyph">●</span>Electrocardiogram (ECG) to screen for poisoning by drugs that affect the QRS or QTc intervals</p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy test in females of childbearing age</p><p></p><p>Urine and serum BZD testing have limited utility due to test characteristics. (See <a class="local">'Role of laboratory benzodiazepine testing'</a> below.)</p><p>Additional tests are obtained based upon historical and clinical findings. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H1869787053"><span class="h2">Role of laboratory benzodiazepine testing</span><span class="headingEndMark"> — </span>Despite widespread use of urine drug screens that include BZDs, laboratory testing has limited value and rarely changes management, similar to testing for other drug use. (See  <a class="medical medical_review" href="/z/d/html/13846.html" rel="external">"Testing for drugs of abuse (DOAs)", section on 'Indications: When is a DOA screen useful (or not)?'</a>.)</p><p class="headingAnchor" id="H4025872236"><span class="h3">Urine testing</span><span class="headingEndMark"> — </span>Most hospital clinical laboratories only have access to qualitative urine BZD screens, which are immunoassays that have poor sensitivity and specificity for identification of a BZD. A positive urine BZD drug screen only indicates recent exposure; it does not confirm causality for acute symptoms, toxicity, or overdose. The most common BZD urine test identifies metabolites of 1,4-BZDs such as <a class="drug drug_general" data-topicid="9726" href="/z/d/drug information/9726.html" rel="external">oxazepam</a>. This test may not detect commonly encountered BZDs such as <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">clonazepam</a>, <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a>, <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">midazolam</a>, or <a class="drug drug_general" data-topicid="8453" href="/z/d/drug information/8453.html" rel="external">alprazolam</a>. More specific screening tests that can detect agents not traditionally measured by common immunoassays are available at some laboratories.</p><p>A number of factors, such as the amount of drug ingested, the presence of co-ingestants, and patient age and weight, can alter pharmacokinetics and affect urine drug tests. In general, BZD metabolites can be detected as early as three hours after ingestion and may remain detectable for up to two weeks [<a href="#rid34">34</a>]. Of note, <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">efavirenz</a> (a non-nucleoside reverse transcriptase inhibitor used to manage human immunodeficiency virus [HIV] infection) as well as <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a> may cause a false-positive result for BZDs on many urine immunoassays [<a href="#rid35">35</a>].</p><p>Although results of urine testing typically do not alter clinical decision-making during acute care, some designer BZDs have been reported to cross-react with commonly used BZD immunoassays. For example, phenazepam, etizolam, pyrazolam, flubromazepam, diclazepam, and delorazepam were detected on an enzyme-linked immunosorbent assay [<a href="#rid36">36</a>]. However, more than 30 designer BZDs have been identified; they have sufficient structural diversity that many would not be expected to cross-react [<a href="#rid37">37</a>]. If confirmatory testing is required, samples should be sent to a laboratory that can perform sophisticated analytical testing (eg, chromatography combined with mass spectrometry) with a request to specifically identify designer BZDs.</p><p class="headingAnchor" id="H4023029389"><span class="h3">Serum testing</span><span class="headingEndMark"> — </span>Serum BZD concentrations are not routinely available in the emergency setting, correlate poorly with clinical findings, do not aid in the acute management, and have long turn-around times. Serum concentrations may be helpful confirmatory forensic tests (eg, a patient who denies ingestion after sedation has improved and BZD poisoning is strongly suspected or in cases of drug-facilitated sexual assault).</p><p class="headingAnchor" id="H7"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The sedative-hypnotic toxidrome is characterized by a physical examination only remarkable for a depressed mental status and unremarkable vital signs (hence the common description "coma with normal vitals"). In any suspected ingestion when the patient cannot provide a history, an exploration of alternative sources of information is warranted, including but not exclusive to emergency medical services, family members, pill bottles if available, medical records, and pharmacy information. Other common ingestions that present similar to BZD poisoning include:</p><p class="bulletIndent1"><span class="glyph">●</span>Ethanol and <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> intoxication, which can be assessed by obtaining serum concentrations. (See  <a class="medical medical_review" href="/z/d/html/333.html" rel="external">"Ethanol intoxication in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6487.html" rel="external">"Ethanol intoxication in children: Clinical features, evaluation, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gamma hydroxybutyrate (GHB) intoxication, which often manifests severe central nervous system depression followed by abrupt awakening. GHB intoxication is difficult to distinguish from other causes of obtundation without a clear history. (See  <a class="medical medical_review" href="/z/d/html/307.html" rel="external">"Gamma hydroxybutyrate (GHB) intoxication"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Atypical antipsychotic agents (eg, <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a>), which are commonly misused and intentionally ingested, can cause sedation as well as tachycardia and anticholinergic delirium. (See  <a class="medical medical_review" href="/z/d/html/304.html" rel="external">"Second-generation (atypical) antipsychotic medication poisoning"</a> and  <a class="medical medical_review" href="/z/d/html/305.html" rel="external">"Anticholinergic poisoning"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">Gabapentin</a>, <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>, <a class="drug drug_general" data-topicid="10057" href="/z/d/drug information/10057.html" rel="external">zolpidem</a>, <a class="drug drug_general" data-topicid="10126" href="/z/d/drug information/10126.html" rel="external">zopiclone</a>, <a class="drug drug_general" data-topicid="8830" href="/z/d/drug information/8830.html" rel="external">eszopiclone</a>, and <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">trazodone</a> are examples of commonly misused sedatives that can only be excluded by history. (See  <a class="medical medical_review" href="/z/d/html/139762.html" rel="external">"Gabapentinoid poisoning and withdrawal"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">Baclofen</a> or phenibut intoxication can cause severe central nervous system depression but is also associated with respiratory depression and disordered movements (eg, myoclonus). (See  <a class="medical medical_review" href="/z/d/html/141081.html" rel="external">"GABA-B agonist (baclofen, phenibut) poisoning and withdrawal"</a>.) </p><p></p><p class="bulletIndent1">Sedation/coma  (<a class="graphic graphic_table graphicRef65571" href="/z/d/graphic/65571.html" rel="external">table 3</a>) and delirium  (<a class="graphic graphic_table graphicRef59893" href="/z/d/graphic/59893.html" rel="external">table 4</a>), common findings in BZD overdose, are found in a wide range of medical and toxicologic conditions. The approach to patients with these symptoms is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5104.html" rel="external">"Stupor and coma in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6225.html" rel="external">"Evaluation of stupor and coma in children"</a> and  <a class="medical medical_review" href="/z/d/html/4824.html" rel="external">"Diagnosis of delirium and confusional states"</a>.)</p><p></p><p>As a synopsis, unless the diagnosis of BZD toxicity is obvious, other life-threatening causes must be considered in the differential diagnosis:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypoglycemia must be excluded in every patient with altered mental status, even if BZD poisoning is suspected.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with profound respiratory depression or cardiopulmonary instability, which is rare with isolated BZD overdoses, the presence of co-ingestants (eg, opioids) or non-toxicologic etiologies should be investigated. (See  <a class="medical medical_review" href="/z/d/html/300.html" rel="external">"Acute opioid intoxication in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6504.html" rel="external">"Opioid intoxication in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Altered mental status in association with fever or leukocytosis raises concern for meningitis or other infections and warrants a thorough evaluation, often including assessment of the cerebral spinal fluid. (See  <a class="medical medical_review" href="/z/d/html/1287.html" rel="external">"Clinical features and diagnosis of acute bacterial meningitis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1284.html" rel="external">"Viral encephalitis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Any focal neurologic findings or seizures raise concern for a central nervous system process such as stroke, intracranial hemorrhage, or encephalitis. (See  <a class="medical medical_review" href="/z/d/html/1083.html" rel="external">"Overview of the evaluation of stroke"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A history of trauma or clinical findings of injuries should prompt obtaining a head computed tomography (CT) scan. (See  <a class="medical medical_review" href="/z/d/html/13854.html" rel="external">"Initial management of trauma in adults"</a>.)</p><p></p><p class="headingAnchor" id="H11"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H12"><span class="h2">Address airway, breathing, and circulation</span><span class="headingEndMark"> — </span>As with any poisoning or potentially critically ill patient, the initial treatment begins with rapidly assessing and addressing the patient's airway, breathing, and circulation. Administer <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> to a patient with altered mental status and concern for signs or symptoms of an opioid exposure (eg, respiratory depression). (See  <a class="medical medical_review" href="/z/d/html/324.html" rel="external">"General approach to drug poisoning in adults"</a> and  <a class="medical medical_review" href="/z/d/html/300.html" rel="external">"Acute opioid intoxication in adults", section on 'Basic measures and antidotal therapy'</a>.)</p><p>In patients who present with anything more than trivial sedation, we suggest establishing intravenous (IV) access and continuous cardiac monitoring. End tidal carbon dioxide (EtCO<sub>2</sub>; ie, capnography) is useful for monitoring patients at risk for hypoventilation. Oxygen should be administered as needed. Placing a nasopharyngeal airway (ie, nasal trumpet) may be sufficient to overcome upper airway obstruction from central nervous system depression and preclude the need for endotracheal intubation. (See  <a class="medical medical_review" href="/z/d/html/267.html" rel="external">"Basic airway management in adults", section on 'Nasopharyngeal airway'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Respiratory depression</strong> – We suggest a trial of parenteral or intranasal <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> in patients with confirmed or suspected BZD overdose complicated by respiratory depression or failure. Naloxone is used to treat an alternative etiology of respiratory depression that may be quickly and safely reversed (eg, opioid co-ingestion).</p><p></p><p class="bulletIndent1">If there is no clinical improvement after <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a>, we do not routinely use <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">flumazenil</a> and prefer to proceed with definitive airway management. However, some experts will administer flumazenil in patients deemed to be at low risk for precipitating BZD withdrawal or seizures in an attempt to prevent endotracheal intubation. (See  <a class="medical medical_review" href="/z/d/html/300.html" rel="external">"Acute opioid intoxication in adults", section on 'Basic measures and antidotal therapy'</a> and <a class="local">'Controversial indications'</a> below.)</p><p></p><p class="bulletIndent1">The decision to perform endotracheal intubation for airway protection and respiratory support is similar to any other critically ill patients after <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> and/or <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">flumazenil</a> has been either tried or excluded.</p><p></p><p class="headingAnchor" id="H13"><span class="h2">Role of decontamination</span><span class="headingEndMark"> — </span>We do not perform routine gastrointestinal decontamination with activated charcoal (AC) in patients with isolated BZD ingestion since intoxication will often improve with supportive care and metabolism of the BZD. Administering AC provides no additional benefits but can increase the risk of aspiration and complicate airway management if the patient becomes more sedated. (See  <a class="medical medical_review" href="/z/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Activated charcoal'</a>.)</p><p>However, AC may be beneficial in selected patients, such as those with a history or suspicion of a life-threatening co-ingestion that AC will adsorb to (eg, <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, etc) and a protected airway (naturally or with a cuffed endotracheal tube). AC is administered orally or via gastric tube at a dose of 1 g/kg.</p><p>Whole-bowel irrigation is generally unnecessary because of the rarity of sustained-release preparations and, if administered, should also be in a patient with a protected airway to prevent aspiration.</p><p class="headingAnchor" id="H14"><span class="h2">Role of antidote (flumazenil)</span></p><p class="headingAnchor" id="H1907491635"><span class="h3">Clinical scenarios</span><span class="headingEndMark"> — </span>Clinicians unfamiliar with <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">flumazenil</a> but contemplating administering it should contact a regional poison control center or consult a medical toxicologist for help with patient selection and dosing. (See <a class="local">'Regional poison control centers'</a> below.)</p><p class="headingAnchor" id="H1173302308"><span class="h4">Commonly accepted indications</span><span class="headingEndMark"> — </span>We use <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">flumazenil</a>, a nonspecific competitive antagonist of the BZD receptor, to reverse BZD sedation in the following clinical scenarios:</p><p class="bulletIndent1"><span class="glyph">●</span>Reverse procedural sedation in patients who do not use BZDs chronically (see  <a class="medical medical_review" href="/z/d/html/264.html" rel="external">"Procedural sedation in adults in the emergency department: General considerations, preparation, monitoring, and mitigating complications", section on 'Anticipating and mitigating Complications'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Young children with an isolated BZD ingestion with severe central nervous system depression or isolated ataxia, <strong>except</strong> those who take BZDs for a seizure disorder or with iatrogenic BZD toxicity from treatment of status epilepticus (see <a class="local">'Use in young children'</a> below)</p><p></p><p class="headingAnchor" id="H643625595"><span class="h4">Controversial indications</span><span class="headingEndMark"> — </span>Some experts use <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">flumazenil</a> in the following select scenarios, although we would not administer flumazenil given the controversy around precipitating BZD withdrawal and seizures (see <a class="local">'Precipitated BZD withdrawal or seizures'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>A patient with suspected but unconfirmed BZD ingestion, no concern for proconvulsant co-ingestion (eg, tricyclic antidepressant [TCA], <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>), and not having a witnessed or suspected seizure. Since the patient typically is unable to provide a history, the clinician should exclude availability of proconvulsant medication from other sources such as asking family members, consulting electronic medical records, or contacting the patient's pharmacy. In this setting, <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">flumazenil</a> administration may avoid extensive and invasive testing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A patient with confirmed BZD ingestion, no proconvulsant co-ingestion (eg, TCA, <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>), and no witnessed or suspected seizure who has respiratory depression or is not protecting their airway. <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">Flumazenil</a> in this setting can improve respiratory drive and airway tone and avoid endotracheal intubation.</p><p></p><p class="headingAnchor" id="H823237611"><span class="h4">Contraindications</span><span class="headingEndMark"> — </span>Experts agree that <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">flumazenil</a> <strong>should not</strong> be administered in the following clinical scenarios:</p><p class="bulletIndent1"><span class="glyph">●</span>As part of "coma cocktail" routinely in all patients with undifferentiated obtundation [<a href="#rid38">38</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Altered mental status with a witnessed or suspected seizure</p><p class="bulletIndent1"><span class="glyph">●</span>Any suspicion for proconvulsant co-ingestion (eg, TCA, <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Patient taking a BZD for a seizure disorder</p><p class="bulletIndent1"><span class="glyph">●</span>Iatrogenic BZD overdose caused by treatment of status epilepticus</p><p></p><p class="headingAnchor" id="H2123183710"><span class="h3">Adult dosing</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients without BZD tolerance and no history of seizure disorder </strong>– In adults, the initial <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">flumazenil</a> dose is 0.2 mg IV given by slow push over one to two minutes. A response is expected in two to five minutes with peak effect at approximately 6 to 10 minutes after dosing.</p><p></p><p class="bulletIndent1">Subsequent doses are 0.3 mg and 0.5 mg IV every one to two minutes to an initial cumulative maximum dose of 1 mg or until the desired effect is achieved [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>BZD-tolerant patient or history of seizure disorder</strong> – We do not administer <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">flumazenil</a> to patients who take BZDs chronically or have a history of a seizure disorder. However, experts who use flumazenil in these patients will lower the starting dose to 0.1 mg IV to decrease the chance of precipitating BZD withdrawal.</p><p></p><p class="bulletIndent1">Subsequent doses are 0.2 mg, 0.3 mg, and 0.5 mg IV at intervals of 10 to 15 minutes, titrated to desired effect. The time interval is increased because these patients are at greater risk of precipitated seizure or agitation with BZD reversal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resedation after </strong><strong>flumazenil</strong> – <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">Flumazenil</a>'s plasma elimination half-life is short (0.7 to 1.3 hours); thus, the duration of effect of a long-acting BZD or a large BZD overdose can exceed that of flumazenil. In the event of resedation, repeat the dosing regimen described above until the desired effect is achieved, but no more than 3 mg of flumazenil should be given within any one hour.</p><p></p><p class="bulletIndent1">A continuous <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">flumazenil</a> infusion (0.25 to 1 mg per hour) is an option for patients with exposures to BZDs with prolonged durations of action or those with hepatic insufficiency with prolonged exposure to BZDs [<a href="#rid40">40,41</a>]. However, we suggest using either intermittent dosing or consulting a medical toxicologist or poison control center whenever a flumazenil infusion is thought to be needed given increased risk of adverse effects from a continuous infusion.</p><p></p><p class="headingAnchor" id="H1505857257"><span class="h3">Use in young children</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">Flumazenil</a> is less likely to cause complications in young children (ie, five years old and younger) as compared with adults because children do not commonly take BZDs chronically. The concern for precipitated seizures is based on adult data; limited evidence suggests that previously healthy children may be less likely to have a seizure after flumazenil administration [<a href="#rid42">42</a>]. Regardless, flumazenil should not be given to a child who takes BZDs for a seizure disorder or with iatrogenic BZD overdose caused by treatment of status epilepticus. Young children (two years old and younger) are also more susceptible to respiratory depression from BZDs [<a href="#rid27">27</a>]. Flumazenil, given as a diagnostic challenge, has been reported to reverse isolated ataxia when the history of BZD ingestion in a child was uncertain [<a href="#rid43">43</a>]. This may prevent an extensive neurologic workup. Flumazenil should be administered in cases where oversedation occurs during procedural sedation using IV BZD. Of note, flumazenil does not consistently reverse respiratory depression caused by BZD overdose [<a href="#rid44">44</a>].</p><p>In children, the initial dose is 0.01 mg/kg given by slow IV push over one to two minutes (maximum dose 0.2 mg). Repeat the initial dose at one-minute (or longer) intervals with up to four repeat doses of 0.005 to 0.01 mg/kg (maximum 0.2 mg) per dose or until the desired effect is achieved. The maximum dose should <strong>not</strong> exceed 1 mg total or 0.05 mg/kg; the lower dose is preferable.</p><p class="headingAnchor" id="H1129896514"><span class="h3">Precipitated BZD withdrawal or seizures</span><span class="headingEndMark"> — </span>The use of <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">flumazenil</a> in a patient with undifferentiated altered mental status remains controversial among experts. Administration of flumazenil can precipitate withdrawal symptoms or seizures in patients who have developed a tolerance to BZDs, have a seizure disorder, have a proconvulsive co-ingestant (eg, TCA), or are receiving BZDs for control of increased intracranial pressure or status epilepticus [<a href="#rid45">45-47</a>].</p><p>In the unlikely scenario of a flumazenil-precipitated sustained seizure, we suggest administering a BZD dose in the upper normal range, <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>, or <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a>. Despite concerns that flumazenil-precipitated seizure, agitation or withdrawal will be difficult to treat due to gamma-aminobutyric acid A (GABA-A) antagonism, <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">flumazenil</a> is a competitive antagonist at the GABA-A receptor, and only 50 percent of the BZD binding sites are occupied by flumazenil after a 1 mg cumulative dose. Therefore, any adverse effects from flumazenil can be overcome by either routine or slightly increased BZD dosing.</p><p>Additionally, <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">flumazenil</a> only binds the BZD site on the GABA-A receptor, which possesses distinct barbiturate and <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> binding sites that also potentiate gamma-aminobutyric acid (GABA) activity. Therefore, any difficult-to-treat seizures can be controlled with <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> or propofol administration [<a href="#rid44">44,48</a>].</p><p>A meta-analysis of 13 trials of <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">flumazenil</a> for adult patients with impaired consciousness due to a suspected or known BZD ingestion (either as a single drug or as part of a multi-drug intoxication) included 994 patients (498 received flumazenil); adverse events were more frequent with flumazenil (25 versus 9 percent), as were serious adverse events (2.4 versus 0.4 percent). Most of the adverse events were transient and mild, including agitation, anxiety, and gastrointestinal symptoms. Out of the 12 serious events in the flumazenil group, seven were narrow complex tachycardia, one was multiple ventricular beats, and one was a decrease in blood pressure, none of which were life threatening. There were three seizures, but these were related to proconvulsant co-ingestions [<a href="#rid49">49</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Argument against </strong><strong>flumazenil</strong><strong> use</strong> – Oral BZD overdose has a low rate of morbidity and mortality, so the risks of <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">flumazenil</a> treatment are felt to outweigh the benefits of earlier arousal. Furthermore, resedation is likely. The patient with a confirmed isolated oral BZD ingestion is not expected to need airway management and will improve with general supportive care and metabolism of the inciting agent. Additionally, in a sedated patient, the clinician can never be completely certain that the patient did not have a proconvulsant co-ingestion, a seizure, an underlying seizure disorder, or a tolerance to BZDs. In trials, the rate of adverse events from flumazenil is relatively high, and the trials did not follow subjects for sufficient duration to evaluate clinical outcomes such as hospital length of stay, time on ventilator, or aspiration pneumonia.</p><p></p><p class="bulletIndent1">The routine use of <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">flumazenil</a> as part of the "coma cocktail" (ie, medications routinely given to unresponsive patients) has been discouraged due to risks of precipitating seizures or BZD withdrawal in the BZD-tolerant patient or patient with a seizure disorder [<a href="#rid38">38</a>]. Instead, aggressive airway control and respiratory support is preferred.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Argument supporting </strong><strong>flumazenil</strong><strong> use</strong> – If the etiology of sedation (or ataxia in a child) is not clearly from a BZD ingestion, the clinician must exclude non-toxicologic etiologies that may need specific treatment. In this case, the purported benefit of <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">flumazenil</a> is to avoid the need for procedures, such as endotracheal intubation, neurologic imaging, and lumbar puncture, if a history can be obtained should the patient's mental status or neurologic impairment return to baseline with reversal of the BZD's sedative effects. In one trial, there was a 27 percent decreased need for intubation with flumazenil compared with placebo [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1">Some experts believe the perceived risk of precipitated BZD withdrawal from <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">flumazenil</a> is overstated and that it is safe to use flumazenil in an obtunded patient with a suspected overdose that does not involve a proconvulsant ingestion, even if the patient is known to have a seizure disorder or use a BZD chronically (although these groups have an increased risk of precipitated BZD withdrawal). Seizure activity was not demonstrated in multiple trials when flumazenil was administered for BZD overdose or for coma from suspected poisoning [<a href="#rid41">41,50-53</a>]. In other studies, the vast majority of patients who had a seizure after flumazenil also had a proconvulsant co-ingestion (specifically TCA) [<a href="#rid54">54-56</a>]. In these trials, even though the rate of adverse events related to precipitated BZD withdrawal from flumazenil was relatively high, these events were mostly agitation, anxiety, and gastrointestinal distress; they were not clinically significant nor difficult to manage.</p><p></p><p class="headingAnchor" id="H1369026413"><span class="h2">Supportive care</span><span class="headingEndMark"> — </span>In cases of isolated BZD overdose, routine supportive care and monitoring is typically all that is necessary. The period of observation and disposition depend upon the clinical scenario. Supportive care is described in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/324.html" rel="external">"General approach to drug poisoning in adults", section on 'Supportive care'</a>.)</p><p class="headingAnchor" id="H2504766806"><span class="h2">No role for enhanced elimination</span><span class="headingEndMark"> — </span>There are no effective techniques to enhance BZD elimination. Forced IV diuresis, multidose AC, and hemodialysis are ineffective at increasing BZD elimination.</p><p class="headingAnchor" id="H15"><span class="h1">DISPOSITION</span><span class="headingEndMark"> — </span>Patients who require mechanical ventilation or have been exposed to a dangerous co-ingestant are admitted to a critical care setting.</p><p>Most patients with an isolated BZD ingestion can be safely discharged or cleared for psychiatric evaluation following an observation period of four to six hours, provided that any concerning symptoms, such as central nervous system depression, have resolved. The patient should be able to ambulate safely by the end of this period. Patients with persistent signs of intoxication beyond six hours should be admitted to a monitored setting until symptoms resolve.</p><p class="headingAnchor" id="H19"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H3373022143"><span class="h2">Regional poison control centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.)</p><p class="headingAnchor" id="H938016617"><span class="h2">Society guideline links</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112689.html" rel="external">"Society guideline links: General measures for acute poisoning treatment"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/114814.html" rel="external">"Society guideline links: Benzodiazepine use disorder and withdrawal"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/114015.html" rel="external">"Society guideline links: Treatment of acute poisoning caused by recreational drug or alcohol use"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacology</strong> – Benzodiazepines (BZD)  (<a class="graphic graphic_table graphicRef69184" href="/z/d/graphic/69184.html" rel="external">table 1</a>) exert their effect via potentiation of the inhibitory activity of the gamma-aminobutyric acid A (GABA-A) receptor. Gamma-aminobutyric acid (GABA) is the chief inhibitory neurotransmitter of the central nervous system. (See <a class="local">'Pharmacology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features of overdose </strong>– Oral BZDs taken in overdose without a co-ingestant rarely cause significant toxicity. The classic presentation of a patient with an isolated BZD overdose consists of central nervous system depression with normal vital signs. Massive overdose, sedative co-ingestant (eg. opioids, ethanol), or intravenous (IV) administration can cause respiratory depression and stupor or coma. (See <a class="local">'Clinical features of overdose'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The definitive diagnosis of BZD poisoning is made on the basis of history and corroborating data in a sedated patient. In the absence of clear corroborating history, BZD poisoning should be considered a diagnosis of exclusion. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory BZD testing</strong> – BZD urine screens have poor sensitivity and specificity for BZD toxicity. A positive urine BZD drug screen only indicates recent exposure and does not confirm causality for acute symptoms, toxicity, or overdose. A negative urine screen does not rule out BZD toxicity since common urine tests identify metabolites of 1,4-BZDs, such as <a class="drug drug_general" data-topicid="9726" href="/z/d/drug information/9726.html" rel="external">oxazepam</a>, and may not detect <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">clonazepam</a>, <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a>, <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">midazolam</a>, or <a class="drug drug_general" data-topicid="8453" href="/z/d/drug information/8453.html" rel="external">alprazolam</a>. (See <a class="local">'Role of laboratory benzodiazepine testing'</a> above and  <a class="medical medical_review" href="/z/d/html/13846.html" rel="external">"Testing for drugs of abuse (DOAs)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis </strong>– Sedation  (<a class="graphic graphic_table graphicRef65571" href="/z/d/graphic/65571.html" rel="external">table 3</a>) and delirium  (<a class="graphic graphic_table graphicRef59893" href="/z/d/graphic/59893.html" rel="external">table 4</a>), common findings in BZD overdose, are found in a wide range of medical and toxicologic conditions. Unless the diagnosis of BZD toxicity is obvious, other life-threatening non-toxicologic causes must be excluded, especially conditions in which diagnostic delay will hold up critical interventions and definitive care. A bedside fingerstick glucose must be checked in any patient with altered mental status. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management – </strong>Treatment is aimed at addressing airway, breathing, and circulation and providing supportive care. In patients with respiratory depression, we suggest a trial of parenteral or intranasal <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> since a concomitant opioid overdose may be present. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1">Routine gastrointestinal decontamination with activated charcoal (AC) has no benefit in oral BZD overdose. AC may be beneficial in selected patients, such as those with a history or suspicion of a life-threatening co-ingestion that AC will absorb (eg, <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>) and a protected airway (naturally or with a cuffed endotracheal tube). (See <a class="local">'Role of decontamination'</a> above.)</p><p></p><p class="bulletIndent1">Most cases of isolated BZD ingestion are managed successfully with supportive care alone. (See <a class="local">'Supportive care'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of antidote (</strong><strong>flumazenil</strong><strong>)</strong> – <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">Flumazenil</a> is a nonspecific competitive antagonist of the BZD receptor that can be used to reverse BZD-induced sedation but can also precipitate BZD withdrawal symptoms and seizures. The use of flumazenil in the setting of overdose remains controversial. In the following patients, we suggest giving flumazenil to avoid more invasive airway procedures (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>) (see <a class="local">'Role of antidote (flumazenil)'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Reverse procedural over-sedation in patients who do not use BZDs chronically</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Children five years old and younger with an isolated BZD ingestion with severe central nervous system depression or isolated ataxia, except those who take BZDs for a seizure disorder or are receiving iatrogenic BZDs for treatment of status epilepticus</p><p></p><p class="bulletIndent1">Generally accepted absolute contraindications to <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">flumazenil</a> are a proconvulsant co-ingestion, sustaining a seizure during course of altered mental status, or receiving BZDs for a seizure disorder, control of increased intracranial pressure, or status epilepticus. (See <a class="local">'Contraindications'</a> above.)</p><p></p><p class="headingAnchor" id="H3801785898"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Stephen J Traub, MD, former section editor of the toxicology program, for 20 years of dedicated service.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Drug Abuse Warning Network: The DAWN Report. April 2004. Benzodiazepine in Drug-Abuse Related Emergency Department Visits: 1995-2002. www.oas.samhsa.gov/2k4benzodiazepinesTrends.pdf (Accessed on May 04, 2009).</li><li><a class="nounderline abstract_t">Lader M. Benzodiazepines revisited--will we ever learn? Addiction 2011; 106:2086.</a></li><li><a class="nounderline abstract_t">Soyka M. Treatment of Benzodiazepine Dependence. N Engl J Med 2017; 376:1147.</a></li><li><a class="nounderline abstract_t">Kaufmann CN, Spira AP, Alexander GC, et al. Emergency department visits involving benzodiazepines and non-benzodiazepine receptor agonists. Am J Emerg Med 2017; 35:1414.</a></li><li><a class="nounderline abstract_t">Friedrich JM, Sun C, Geng X, et al. Child and adolescent benzodiazepine exposure and overdose in the United States: 16 years of poison center data. Clin Toxicol (Phila) 2020; 58:725.</a></li><li><a class="nounderline abstract_t">Hevers W, Lüddens H. The diversity of GABAA receptors. Pharmacological and electrophysiological properties of GABAA channel subtypes. Mol Neurobiol 1998; 18:35.</a></li><li><a class="nounderline abstract_t">Smith TA. Type A gamma-aminobutyric acid (GABAA) receptor subunits and benzodiazepine binding: significance to clinical syndromes and their treatment. Br J Biomed Sci 2001; 58:111.</a></li><li><a class="nounderline abstract_t">Ali NJ, Olsen RW. Chronic benzodiazepine treatment of cells expressing recombinant GABA(A) receptors uncouples allosteric binding: studies on possible mechanisms. J Neurochem 2001; 79:1100.</a></li><li><a class="nounderline abstract_t">Olsen RW. GABA-benzodiazepine-barbiturate receptor interactions. J Neurochem 1981; 37:1.</a></li><li><a class="nounderline abstract_t">Potokar J, Coupland N, Wilson S, et al. Assessment of GABA(A)benzodiazepine receptor (GBzR) sensitivity in patients on benzodiazepines. Psychopharmacology (Berl) 1999; 146:180.</a></li><li><a class="nounderline abstract_t">Snead OC 3rd, Nichols AC, Liu CC. gamma-Hydroxybutyric acid binding sites: interaction with the GABA-benzodiazepine-picrotoxin receptor complex. Neurochem Res 1992; 17:201.</a></li><li><a class="nounderline abstract_t">Chouinard G, Lefko-Singh K, Teboul E. Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem. Cell Mol Neurobiol 1999; 19:533.</a></li><li class="breakAll">Wynn G, Oesterheld J, Cozza K, Armstong G. Clinical manual of drug interaction principles for medical practice. Chapters 2, 3, 19. American psychiatric publishing Inc, Washington, DC 2009.</li><li><a class="nounderline abstract_t">Nordt SP, Clark RF. Midazolam: a review of therapeutic uses and toxicity. J Emerg Med 1997; 15:357.</a></li><li><a class="nounderline abstract_t">Bauer TM, Ritz R, Haberthür C, et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet 1995; 346:145.</a></li><li><a class="nounderline abstract_t">Fukasawa T, Suzuki A, Otani K. Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther 2007; 32:333.</a></li><li><a class="nounderline abstract_t">Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38:41.</a></li><li><a class="nounderline abstract_t">Greenblatt DJ, Shader RI, Divoll M, Harmatz JS. Benzodiazepines: a summary of pharmacokinetic properties. Br J Clin Pharmacol 1981; 11 Suppl 1:11S.</a></li><li class="breakAll">The Center for Forensic Science Research &amp; Education Novel Psychoactive Substances Trends Reports, https://www.npsdiscovery.org/reports/trend-reports/ (Accessed on June 08, 2022).</li><li><a class="nounderline abstract_t">Aldy K, Mustaquim D, Campleman S, et al. Notes from the Field: Illicit Benzodiazepines Detected in Patients Evaluated in Emergency Departments for Suspected Opioid Overdose - Four States, October 6, 2020-March 9, 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1177.</a></li><li><a class="nounderline abstract_t">Carpenter JE, Murray BP, Dunkley C, et al. Designer benzodiazepines: a report of exposures recorded in the National Poison Data System, 2014-2017. Clin Toxicol (Phila) 2019; 57:282.</a></li><li><a class="nounderline abstract_t">Mérette SAM, Thériault S, Piramide LEC, et al. Bromazolam Blood Concentrations in Postmortem Cases-A British Columbia Perspective. J Anal Toxicol 2023; 47:385.</a></li><li><a class="nounderline abstract_t">Yu X, Greenblatt HK, Greenblatt DJ. Designer benzodiazepines: an update. Expert Rev Clin Pharmacol 2023; 16:109.</a></li><li><a class="nounderline abstract_t">Ehlers PF, Deitche A, Wise LM, et al. Notes from the Field: Seizures, Hyperthermia, and Myocardial Injury in Three Young Adults Who Consumed Bromazolam Disguised as Alprazolam - Chicago, Illinois, February 2023. MMWR Morb Mortal Wkly Rep 2024; 72:1392.</a></li><li><a class="nounderline abstract_t">Levine M, Lovecchio F. New Designer Drugs. Emerg Med Clin North Am 2021; 39:677.</a></li><li class="breakAll">Center for Forensic Science Research and Education, Novel Psychoactive Substances,  2021 Q4 Benzodiazepines Trend Report. https://www.npsdiscovery.org/wp-content/uploads/2022/02/2021-Q4_NPS-Benzodiazepines_Trend-Report.pdf (Accessed on April 04, 2022).</li><li><a class="nounderline abstract_t">Wiley CC, Wiley JF 2nd. Pediatric benzodiazepine ingestion resulting in hospitalization. J Toxicol Clin Toxicol 1998; 36:227.</a></li><li><a class="nounderline abstract_t">Park TW, Saitz R, Ganoczy D, et al. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ 2015; 350:h2698.</a></li><li><a class="nounderline abstract_t">Jones CM, McAninch JK. Emergency Department Visits and Overdose Deaths From Combined Use of Opioids and Benzodiazepines. Am J Prev Med 2015; 49:493.</a></li><li><a class="nounderline abstract_t">Jones CM, Paulozzi LJ, Mack KA, Centers for Disease Control and Prevention (CDC). Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse-related emergency department visits and drug-related deaths - United States, 2010. MMWR Morb Mortal Wkly Rep 2014; 63:881.</a></li><li><a class="nounderline abstract_t">Höjer J, Baehrendtz S, Gustafsson L. Benzodiazepine poisoning: experience of 702 admissions to an intensive care unit during a 14-year period. J Intern Med 1989; 226:117.</a></li><li><a class="nounderline abstract_t">Wang SH, Chen WS, Tang SE, et al. Benzodiazepines Associated With Acute Respiratory Failure in Patients With Obstructive Sleep Apnea. Front Pharmacol 2018; 9:1513.</a></li><li><a class="nounderline abstract_t">Riker RR, Fraser GL. Adverse events associated with sedatives, analgesics, and other drugs that provide patient comfort in the intensive care unit. Pharmacotherapy 2005; 25:8S.</a></li><li><a class="nounderline abstract_t">Garzone PD, Kroboth PD. Pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 1989; 16:337.</a></li><li><a class="nounderline abstract_t">Blank A, Hellstern V, Schuster D, et al. Efavirenz treatment and false-positive results in benzodiazepine screening tests. Clin Infect Dis 2009; 48:1787.</a></li><li><a class="nounderline abstract_t">O'Connor LC, Torrance HJ, McKeown DA. ELISA Detection of Phenazepam, Etizolam, Pyrazolam, Flubromazepam, Diclazepam and Delorazepam in Blood Using Immunalysis® Benzodiazepine Kit. J Anal Toxicol 2016; 40:159.</a></li><li><a class="nounderline abstract_t">Pérez Orts M, van Asten A, Kohler I. The Evolution Toward Designer Benzodiazepines in Drug-Facilitated Sexual Assault Cases. J Anal Toxicol 2023; 47:1.</a></li><li><a class="nounderline abstract_t">Sivilotti ML. Flumazenil, naloxone and the 'coma cocktail'. Br J Clin Pharmacol 2016; 81:428.</a></li><li class="breakAll">Romazicon package insert, Roche Pharmaceuticals. https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020073s016lbl.pdf (Accessed on December 05, 2022).</li><li><a class="nounderline abstract_t">Maxa JL, Ogu CC, Adeeko MA, Swaner TG. Continuous-infusion flumazenil in the management of chlordiazepoxide toxicity. Pharmacotherapy 2003; 23:1513.</a></li><li><a class="nounderline abstract_t">Höjer J, Baehrendtz S, Magnusson A, Gustafsson LL. A placebo-controlled trial of flumazenil given by continuous infusion in severe benzodiazepine overdosage. Acta Anaesthesiol Scand 1991; 35:584.</a></li><li><a class="nounderline abstract_t">Kreshak AA, Tomaszewski CA, Clark RF, Cantrell FL. Flumazenil administration in poisoned pediatric patients. Pediatr Emerg Care 2012; 28:448.</a></li><li><a class="nounderline abstract_t">Regina A, Lee D, Sud P, Crevi D. Flumazenil Use for Isolated Ataxia in a Child. Pediatr Emerg Care 2016; 32:e13.</a></li><li><a class="nounderline abstract_t">Shalansky SJ, Naumann TL, Englander FA. Effect of flumazenil on benzodiazepine-induced respiratory depression. Clin Pharm 1993; 12:483.</a></li><li><a class="nounderline abstract_t">Weinbroum AA, Flaishon R, Sorkine P, et al. A risk-benefit assessment of flumazenil in the management of benzodiazepine overdose. Drug Saf 1997; 17:181.</a></li><li><a class="nounderline abstract_t">Seger DL. Flumazenil--treatment or toxin. J Toxicol Clin Toxicol 2004; 42:209.</a></li><li><a class="nounderline abstract_t">Kreshak AA, Cantrell FL, Clark RF, Tomaszewski CA. A poison center's ten-year experience with flumazenil administration to acutely poisoned adults. J Emerg Med 2012; 43:677.</a></li><li class="breakAll">Romazicon package insert. Roche Pharmaceuticals. www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=6844 (Accessed on May 05, 2009).</li><li><a class="nounderline abstract_t">Penninga EI, Graudal N, Ladekarl MB, Jürgens G. Adverse Events Associated with Flumazenil Treatment for the Management of Suspected Benzodiazepine Intoxication--A Systematic Review with Meta-Analyses of Randomised Trials. Basic Clin Pharmacol Toxicol 2016; 118:37.</a></li><li><a class="nounderline abstract_t">Höjer J, Baehrendtz S, Matell G, Gustafsson LL. Diagnostic utility of flumazenil in coma with suspected poisoning: a double blind, randomised controlled study. BMJ 1990; 301:1308.</a></li><li><a class="nounderline abstract_t">Ritz R, Zuber M, Elsasser S, Scollo-Lavizzari G. Use of flumazenil in intoxicated patients with coma. A double-blind placebo-controlled study in ICU. Intensive Care Med 1990; 16:242.</a></li><li><a class="nounderline abstract_t">Winkler E, Almog S, Kriger D, et al. Use of flumazenil in the diagnosis and treatment of patients with coma of unknown etiology. Crit Care Med 1993; 21:538.</a></li><li><a class="nounderline abstract_t">Weinbroum A, Rudick V, Sorkine P, et al. Use of flumazenil in the treatment of drug overdose: a double-blind and open clinical study in 110 patients. Crit Care Med 1996; 24:199.</a></li><li><a class="nounderline abstract_t">Spivey WH, Roberts JR, Derlet RW. A clinical trial of escalating doses of flumazenil for reversal of suspected benzodiazepine overdose in the emergency department. Ann Emerg Med 1993; 22:1813.</a></li><li><a class="nounderline abstract_t">Spivey WH. Flumazenil and seizures: analysis of 43 cases. Clin Ther 1992; 14:292.</a></li><li><a class="nounderline abstract_t">Treatment of benzodiazepine overdose with flumazenil. The Flumazenil in Benzodiazepine Intoxication Multicenter Study Group. Clin Ther 1992; 14:978.</a></li></ol></div><div id="topicVersionRevision">Topic 314 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="www.oas.samhsa.gov/2k4benzodiazepinesTrends.pdf" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Drug Abuse Warning Network: The DAWN Report. April 2004. Benzodiazepine in Drug-Abuse Related Emergency Department Visits: 1995-2002. www.oas.samhsa.gov/2k4benzodiazepinesTrends.pdf (Accessed on May 04, 2009).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21714826" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Benzodiazepines revisited--will we ever learn?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28328330" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Treatment of Benzodiazepine Dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28476551" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Emergency department visits involving benzodiazepines and non-benzodiazepine receptor agonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31612741" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Child and adolescent benzodiazepine exposure and overdose in the United States: 16 years of poison center data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9824848" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The diversity of GABAA receptors. Pharmacological and electrophysiological properties of GABAA channel subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11440203" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Type A gamma-aminobutyric acid (GABAA) receptor subunits and benzodiazepine binding: significance to clinical syndromes and their treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11739624" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Chronic benzodiazepine treatment of cells expressing recombinant GABA(A) receptors uncouples allosteric binding: studies on possible mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6265597" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : GABA-benzodiazepine-barbiturate receptor interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10525753" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Assessment of GABA(A)benzodiazepine receptor (GBzR) sensitivity in patients on benzodiazepines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1311434" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : gamma-Hydroxybutyric acid binding sites: interaction with the GABA-benzodiazepine-picrotoxin receptor complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10379424" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10379424" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9258787" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Midazolam: a review of therapeutic uses and toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7603229" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prolonged sedation due to accumulation of conjugated metabolites of midazolam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17635335" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10668858" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6133528" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Benzodiazepines: a summary of pharmacokinetic properties.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6133528" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Benzodiazepines: a summary of pharmacokinetic properties.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34437520" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Notes from the Field: Illicit Benzodiazepines Detected in Patients Evaluated in Emergency Departments for Suspected Opioid Overdose - Four States, October 6, 2020-March 9, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30430874" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Designer benzodiazepines: a report of exposures recorded in the National Poison Data System, 2014-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36715069" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Bromazolam Blood Concentrations in Postmortem Cases-A British Columbia Perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36649662" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Designer benzodiazepines: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38175814" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Notes from the Field: Seizures, Hyperthermia, and Myocardial Injury in Three Young Adults Who Consumed Bromazolam Disguised as Alprazolam - Chicago, Illinois, February 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34215409" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : New Designer Drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34215409" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : New Designer Drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9656979" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pediatric benzodiazepine ingestion resulting in hospitalization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26063215" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26143953" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Emergency Department Visits and Overdose Deaths From Combined Use of Opioids and Benzodiazepines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25299603" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse-related emergency department visits and drug-related deaths - United States, 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2769176" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Benzodiazepine poisoning: experience of 702 admissions to an intensive care unit during a 14-year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30666205" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Benzodiazepines Associated With Acute Respiratory Failure in Patients With Obstructive Sleep Apnea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15899744" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Adverse events associated with sedatives, analgesics, and other drugs that provide patient comfort in the intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2567646" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Pharmacokinetics of the newer benzodiazepines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19432553" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Efavirenz treatment and false-positive results in benzodiazepine screening tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26518230" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : ELISA Detection of Phenazepam, Etizolam, Pyrazolam, Flubromazepam, Diclazepam and Delorazepam in Blood Using Immunalysis®Benzodiazepine Kit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35294022" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The Evolution Toward Designer Benzodiazepines in Drug-Facilitated Sexual Assault Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26469689" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Flumazenil, naloxone and the 'coma cocktail'.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26469689" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Flumazenil, naloxone and the 'coma cocktail'.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14620397" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Continuous-infusion flumazenil in the management of chlordiazepoxide toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1686131" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A placebo-controlled trial of flumazenil given by continuous infusion in severe benzodiazepine overdosage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22531190" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Flumazenil administration in poisoned pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27898636" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Flumazenil Use for Isolated Ataxia in a Child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8354035" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Effect of flumazenil on benzodiazepine-induced respiratory depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9306053" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A risk-benefit assessment of flumazenil in the management of benzodiazepine overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15214628" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Flumazenil--treatment or toxin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22766408" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A poison center's ten-year experience with flumazenil administration to acutely poisoned adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22766408" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A poison center's ten-year experience with flumazenil administration to acutely poisoned adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26096314" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Adverse Events Associated with Flumazenil Treatment for the Management of Suspected Benzodiazepine Intoxication--A Systematic Review with Meta-Analyses of Randomised Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1980218" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Diagnostic utility of flumazenil in coma with suspected poisoning: a double blind, randomised controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2113543" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Use of flumazenil in intoxicated patients with coma. A double-blind placebo-controlled study in ICU.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8097157" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Use of flumazenil in the diagnosis and treatment of patients with coma of unknown etiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8605789" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Use of flumazenil in the treatment of drug overdose: a double-blind and open clinical study in 110 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8239101" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A clinical trial of escalating doses of flumazenil for reversal of suspected benzodiazepine overdose in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1611650" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Flumazenil and seizures: analysis of 43 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1286503" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Treatment of benzodiazepine overdose with flumazenil. The Flumazenil in Benzodiazepine Intoxication Multicenter Study Group.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
